GlassScriptPhysician profile
Francesca Desire
NPI 1174269195
$10,245.79
in general payments reported to CMS, 2019-2025
30 companies · $3,355 in 2025
The $3,355 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,258 · 2023: $2,403 · 2024: $3,230 · 2025: $3,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,788 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,788.34 |
| Education | $199.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,521.28 | 2022-2025 | |
| Janssen Biotech, INC. | $1,583.57 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $702.18 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $661.54 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $547.63 | 2023-2025 | Omvoh |
| Pfizer INC. | $540.09 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $520.60 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $500.87 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $405.75 | 2023-2025 | Tremfya, Stelara |
| Genzyme Corporation | $345.03 | 2022-2025 | |
| Celltrion USA INC. | $299.91 | 2023-2025 | Vegzelma, Yuflyma |
| Evoke Pharma, INC. | $225.21 | 2023-2025 | Gimoti |
| Aimmune Therapeutics, INC. | $201.97 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $184.21 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $180.38 | 2022-2025 | Sucraid, Sucraid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $122.28 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $121.86 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $105.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $93.07 | 2023-2025 | Hadlima |
| Nestle Healthcare Nutrition INC. | $57.97 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $57.78 | 2023-2024 | Linzess |
| Shield Therapeutics INC | $46.43 | 2023-2024 | Accrufer |
| Redhill Biopharma INC. | $40.92 | 2022-2023 | Talicia |
| Vivus LLC | $36.30 | 2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $32.54 | 2024-2025 | Bylvay, Iqirvo |
| Fresenius Kabi USA, LLC | $29.98 | 2024 | Idacio |
| Ferring Pharmaceuticals INC. | $22.39 | 2022 | |
| Daiichi Sankyo INC. | $21.00 | 2023 | Injectafer |
| Novo Nordisk INC | $20.62 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $16.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Desire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.